{"id":388997,"date":"2024-12-30T00:00:00","date_gmt":"2024-12-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0011-2024-biopharma-ovarian-cancer-disease-landscape-forecast-g7-2024\/"},"modified":"2026-03-31T10:27:32","modified_gmt":"2026-03-31T10:27:32","slug":"dlsfon0011-2024-biopharma-ovarian-cancer-disease-landscape-forecast-g7-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0011-2024-biopharma-ovarian-cancer-disease-landscape-forecast-g7-2024\/","title":{"rendered":"Ovarian Cancer | Disease Landscape &#038; Forecast | G7 | 2024"},"content":{"rendered":"<p>The treatment of ovarian cancer has been transformed by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca \/ Merck &#038; Co.), niraparib (Zejula; GSK), and rucaparib (Rubraca; Pharma&#038;), particularly for patients with HRD and deleterious <em>BRCA<\/em> mutations. A highly promising biomarker, the folate receptor-alpha (FR\u03b1) protein is now a target in the treatment of advanced disease. In November 2022, mirvetuximab soravtansine (Elahere; ImmunoGen \/ AbbVie) entered the U.S. market as the first ADC targeting patients with high FR\u03b1-expressing tumors (TPS \u2265 75%; PS2+). A second FR\u03b1-targeted ADC, luveltamab tazevibulin (Luvelta; Sutro Biopharma), is expected to induce antitumor responses in a broader FR\u03b1-expressing population (TPS\u00a0> 25%), thus increasing the number of patients eligible for treatment.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What is the size of the clinically and commercially relevant drug-treatable ovarian cancer population, and how will drug-treatment rates change over time?<\/li>\n<li>What is the current treatment landscape for ovarian cancer? What are interviewed experts\u2019 insights on current therapies?<\/li>\n<li>What are the most promising agents in the late-phase pipeline, and how will they shape the future of the ovarian cancer market?<\/li>\n<li>What are the main drivers of and constraints in the treatment of ovarian cancer, and how will this market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Geography:<\/strong> United States, EU5, Japan<\/p>\n<p><strong>Primary research:<\/strong> ~18 country-specific interviews with thought-leading medical oncologists. Supported by survey data collected for this and other Clarivate research.<\/p>\n<p><strong>Epidemiology:<\/strong> Diagnosed incidence by country and disease stage; clinically and market-relevant drug-treatable populations.<\/p>\n<p><strong>Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key ovarian cancer therapies through 2033, segmented by brands \/ generics \/ biosimilars and epidemiological subpopulations.<\/p>\n<p><strong>Drug treatments:<\/strong> Coverage of key current and emerging therapies.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key features<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-388997","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ovarian-cancer","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/388997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/388997\/revisions"}],"predecessor-version":[{"id":575846,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/388997\/revisions\/575846"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=388997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}